The effects of allopurinol treatment on mortality among patients with gout remain uncertain, with a new meta-analysis finding conflicting results. In a systematic review of the literature that ...

Please provide your email address to receive an email when new articles are posted on . Allopurinol is noninferior to febuxostat for gout when dosed appropriately as part of a treat-to-target strategy ...

Please provide your email address to receive an email when new articles are posted on . “A meta-analysis of randomized controlled trials reporting on the comparison of allopurinol or oxypurinol with ...

Allopurinol hypersensitivity syndrome (AHS) is characterized by severe rash, fever, eosinophilia, hepatitis, and renal failure. [1] It is a feared, albeit rare, complication of therapy and is ...

Among patients with gout, allopurinol use is associated with a lower risk for urolithiasis compared with benzbromarone. Among patients with gout, allopurinol use is associated with a lower risk for ...

July 31, 2012 — Allopurinol hypersensitivity syndrome (AHS), a rare but potentially fatal adverse reaction in patients beginning allopurinol therapy for gout, might be largely avoided by keying the ...

In a study of patients hospitalized with acute gout flares and who had prescriptions for allopurinol, those who had their allopurinol dosages decreased had a higher rate of gout flares within 3 months ...

There was an increase in all-cause mortality among dose escalators (hazard ratio, 1.08; 95% confidence interval, 1.01 to 1.17). Similar effect sizes were seen for incidence of cardiovascular-related ...

BARCELONA, Spain—The gout drug allopurinol on top of usual care does not improve cardiovascular outcomes in patients over age 60 who do not have gout, the ALL-HEART trial confirms. The long-running ...

Racial disparities in gout and gout treatment are an ongoing but tractable problem, research at the 2025 American College of ...

Credit: Shutterstock. The investigational drug AR882 appeared more effective and safer than allopurinol monotherapy in a phase 2 trial. A novel selective URAT1 inhibitor, AR882, further reduces serum ...

gout RA in hand Linked to small increase in mortality; at 2 years, 31% of dose escalators achieved serum urate goal. HealthDay News — Allopurinol dose escalation is not associated with reductions in ...